檢索結果 - Mohammed Milhem

Refine Results
  1. 1
    Work-related musculoskeletal disorders among physical therapists: A comprehensive narrative review

    Work-related musculoskeletal disorders among physical therapists: A comprehensive narrative review 由 Mohammed Milhem, Leonid Kalichman, David Ezra, Deborah Alperovitch‐Najenson

    出版 2016
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    Current status of intralesional agents in treatment of malignant melanoma

    Current status of intralesional agents in treatment of malignant melanoma 由 Misam Zawit, Umang Swami, Hassan Awada, Joyce Arnouk, Mohammed Milhem, Yousef Zakharia

    出版 2021
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease

    Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease 由 Sneha Phadke, Ramez Ghabour, Brian L. Swick, Andrea Swenson, Mohammed Milhem, Yousef Zakharia

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers

    Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers 由 Safinur Atay, Daniel W. Wilkey, Mohammed Milhem, Michael L. Merchant, Andrew K. Godwin

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Improved survival for extremity soft tissue sarcoma treated in high‐volume facilities

    Improved survival for extremity soft tissue sarcoma treated in high‐volume facilities 由 Tyler Abarca, Yubo Gao, Varun Monga, Munir R. Tanas, Mohammed Milhem, Benjamin J. Miller

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A

    Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A 由 Mohammed Milhem, Nadim Mahmud, Donald Lavelle, Hiroto Araki, Joseph DeSimone, Yogen Saunthararajah, Ronald Hoffman

    出版 2004
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents

    Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents 由 Hiroto Araki, Nadim Mahmud, Mohammed Milhem, Rafael Núñez, Mingjiang Xu, Craig A. Beam, Robert S. Hoffman

    出版 2006
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)

    Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide) 由 Chang Xia, Roberto A. Leon‐Ferre, Douglas Laux, Jeremy Michael Deutsch, Bruce A. Smith, Melanie Frees, Mohammed Milhem

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial

    Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial 由 Espen B. Ellingsen, Steven O’Day, Artur Mezheyeuski, Agnieszka Gromadka, Trevor Clancy, Timothy S. Kristedja, Mohammed Milhem, Yousef Zakharia

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Epigenetic Silencing of the Human <i>NOS2</i> Gene: Rethinking the Role of Nitric Oxide in Human Macrophage Inflammatory Responses

    Epigenetic Silencing of the Human <i>NOS2</i> Gene: Rethinking the Role of Nitric Oxide in Human Macrophage Inflammatory Responses 由 Thomas Groß, Karol Kremens, Linda S. Powers, Brandi Brink, Tina Knutson, Frederick E. Domann, Robert A. Philibert, Mohammed Milhem, Martha M. Monick

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma

    Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma 由 Warren Chow, Paul Frankel, Chris Ruel, Dejka M. Araujo, Mohammed Milhem, Scott H. Okuno, Lee Hartner, Samir D. Undevia, Arthur P. Staddon

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

    Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma 由 Igor Puzanov, Mohammed Milhem, David R. Minor, Omid Hamid, Li Ai, Lisa Chen, Michael Chastain, Kevin Gorski, Abraham Anderson, Jeffrey Chou, Howard L. Kaufman, Robert H.I. Andtbacka

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models

    Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models 由 Joshua D. Schoenfeld, Zita A. Sibenaller, Kranti A. Mapuskar, Megan D. Bradley, Brett A. Wagner, Garry R. Buettner, Varun Monga, Mohammed Milhem, Douglas R. Spitz, Bryan G. Allen

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

    Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unres... 由 Robert H.I. Andtbacka, Sanjiv S. Agarwala, David W. Ollila, Sigrun Hallmeyer, Mohammed Milhem, Thomas Amatruda, John Nemunaitis, Kevin J. Harrington, Lisa Chen, Mark Shilkrut, Merrick I. Ross, Howard L. Kaufman

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate‐grade or high‐grade liposarcoma

    Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate‐grade or high‐grade liposarcoma 由 Brian L. Samuels, Sant P. Chawla, Neeta Somaiah, Arthur P. Staddon, Keith M. Skubitz, Mohammed Milhem, Peter K. Kaiser, David C. Portnoy, Dennis A. Priebat, Mark S. Walker, Edward J. Stepanski

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

    Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials 由 Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine, James N. Atkins, Mohammed Milhem, Balkrishna Jahagirdar, Cristina R. Antonescu, Elise Horvath, William D. Tap, Gary K. Schwartz, Howard Streicher

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Cancer Cells Resist Mechanical Destruction in Circulation via RhoA/Actomyosin-Dependent Mechano-Adaptation

    Cancer Cells Resist Mechanical Destruction in Circulation via RhoA/Actomyosin-Dependent Mechano-Adaptation 由 Devon L. Moose, Benjamin L. Krog, Taehyung Kim, Lei Zhao, Sophia Williams‐Perez, Gretchen Burke, Lillian Rhodes, Marion Vanneste, Patrick Breheny, Mohammed Milhem, Christopher S. Stipp, Amy C. Rowat, Michael D. Henry

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis

    Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis 由 Marion Vanneste, Charlotte R. Feddersen, Afshin Varzavand, Elliot Y. Zhu, Tyler M. Foley, Lei Zhao, Kathleen H. Holt, Mohammed Milhem, Robert C. Piper, Christopher S. Stipp, Adam J. Dupuy, Michael D. Henry

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    TAZ and YAP are frequently activated oncoproteins in sarcomas

    TAZ and YAP are frequently activated oncoproteins in sarcomas 由 Colleen Fullenkamp, Sarah L. Hall, Omar Jaber, Brittany L. Pakalniskis, Erica Savage, Johanna Savage, Georgina Ofori‐Amanfo, Allyn M. Lambertz, Stephanie D. Ivins, Christopher S. Stipp, Benjamin J. Miller, Mohammed Milhem, Munir R. Tanas

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

    Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial 由 Robert H.I. Andtbacka, Merrick Ross, Igor Puzanov, Mohammed Milhem, Frances A. Collichio, Keith A. Delman, Thomas Amatruda, Jonathan S. Zager, Lee D. Cranmer, Eddy C. Hsueh, Lisa Chen, Mark Shilkrut, Howard L. Kaufman

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: